Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2025 09:00 ET | Source: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Orchestra BioMed’s Virtue® Sirolimus AngioInfusion Balloon™ (“Virtue SAB”) is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA...
April 28, 2025 16:30 ET | Source: Orchestra BioMed Holdings, Inc.

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
April 23, 2025 09:00 ET | Source: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular riskHRS Satellite Symposium will feature leading...
April 22, 2025 07:00 ET | Source: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular riskBDD also encompasses...
March 31, 2025 16:21 ET | Source: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact...
February 20, 2025 08:00 ET | Source: Orchestra BioMed Holdings, Inc.

Orchestra BioMed to Present at Upcoming Investor Conferences

NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
February 18, 2025 08:00 ET | Source: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy and safety of atrioventricular interval modulation (“AVIM”) therapy for patients who have uncontrolled...
February 12, 2025 10:43 ET | Source: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Late-breaking oral presentation features echocardiographic data analysis showing favorable impact of AVIM therapy on MODERATO II study patients with diastolic dysfunction, a key component in the...
February 05, 2025 08:00 ET | Source: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development (“R&D”) collaborations aligned with Orchestra BioMed’s...
December 09, 2024 07:00 ET | Source: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting

NEW HOPE, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact...